Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865628 | 0.89 | APLNR (0.48) | CD274APLNRPTPN1ALDH1A1HTR2A | |
| SCHEMBL28915772 | 0.85 | APLNR (0.57) | APLNRPTPN1KDM4EALDH1A1 | |
| SCHEMBL14230496 | 0.82 | CD274 (0.53) | CD274APLNRPTPN1KDM4E | |
| SCHEMBL21425529 | 0.79 | DHFR (0.37) | CD274APLNRPTPN1HTR2AHTR2C | |
| SCHEMBL31114343 | 0.78 | APLNR (0.75) | APLNRHTTKDM4EALDH1A1HTR2A | |
| SCHEMBL3188344 | 0.78 | CYP1A2 (0.55) | CD274KDM4EALDH1A1 | |
| SCHEMBL28155887 | 0.77 | PTPN1 (0.49) | CD274APLNRPTPN1KDM4E | |
| SCHEMBL21225382 | 0.75 | APLNR (0.43) | CD274APLNRPTPN1 | |
| SCHEMBL13814620 | 0.75 | PTPN1 (0.49) | CD274APLNRPTPN1ALDH1A1HTR2A | |
| SCHEMBL22634028 | 0.73 | PTPN1 (0.47) | APLNRPTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | CD274 3718/4885APLNR 3436/4885PTPN1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.